类风湿关节炎继发骨质疏松症临床防治药物研究进展  

Research progress of drugs for preventing and treating secondary osteoporosis in rheumatoid arthritis

作　　者：徐子涵 商玮[2] 赵智明[2] 陆乐[2] 沈俊逸[2] 蔡辉 XU Zihan;SHANG Wei;ZHAO Zhiming;LU Le;SHEN Junyi;CAI Hui(The First Clinical Medical College of Nanjing University of Traditional Chinese Medicine, Nanjing 210002, China;Department of Integrated Traditional Chinese and Western Medicine, Eastern Theater General Hospital, PLA, Nanjing 210002, China)

机构地区：[1]南京中医药大学第一临床医学院,江苏南京210002 [2]东部战区总医院(原南京军区南京总医院)中西医结合科,江苏南京210002

出　　处：《中国骨质疏松杂志》2022年第4期580-584,595,共6页Chinese Journal of Osteoporosis

基　　金：军队系统国家中医药管理局重点专科(专病)建设项目(2007ZDZB001)。

摘　　要：骨质疏松症是类风湿关节炎主要的合并症之一,RA疾病进展及治疗过程皆会对骨质结构、骨代谢造成影响,导致RA患者有较高的骨质疏松症和骨折的发病率。RA继发骨质疏松症的防治已成为目前临床工作中的难点。近年来,新型药物的研发不断深入为RA继发骨质疏松症的治疗带来新的选择。本文从改变病情抗风湿药对骨骼健康的影响和RA继发骨质疏松的防治药物的角度,对现有的相关临床研究进展作一综述,为临床用药提供参考。Osteoporosis is one of the main comorbidities of rheumatoid arthritis(RA).The disease progression and the therapeutic process of RA will affect bone structure and bone metabolism,which leads to a higher incidence of osteoporosis and fractures in RA patients.The prevention and treatment of secondary osteoporosis in RA has become an obstacle in the current clinical work.In recent years,the research and development of new drugs has become deeper and deeper,which provides new options for the treatment of secondary osteoporosis in RA.This article reviews the current progress of related clinical research from the perspective of the effects of disease-modifying antirheumatic drugs on bone health and the prevention and treatment of osteoporosis in RA,in order to provide references for clinical use.

关 键 词：类风湿关节炎 骨质疏松症 药物防治 生物制剂 双膦酸盐 特立帕肽 地舒单抗 

分 类 号：R681[医药卫生—骨科学]